Gross margin of Sobi 2009-2023
The gross margin of Swedish biopharmaceutical company Sobi was down at the lowest point in 2011 at 51 percent, but then generally increased the following years. In 2023, the gross margin of Sobi stood at 77 percent. The company's full name is Swedish Orphan Biovitrum AB. Sobi is specialized on the treatment of rare diseases.